Biogenic Selenium Nanoparticles Attenuate Aβ25–35-Induced Toxicity in PC12 Cells via Akt/CREB/BDNF Signaling Pathway
- 26 November 2022
- journal article
- research article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 40 (6) , 1869-1881
Abstract
Deposition of aggregated amyloid beta (Aβ) protein is considered to be a major causative factor that is associated with the development of oxidative stress and neuroinflammation in the pathogenesis of Alzheimer’s disease (AD). Selenium nanoparticles (SeNPs) have been experimentally using for treatment of neurological disease due to their low toxicity, high bioavailability, and multiple bioactivities. This study was conducted to investigate the protective effects of biogenic SeNPs by Lactobacillus casei ATCC 393 against Aβ25–35-induced toxicity in PC12 cells and its association with oxidative stress and inflammation. The results showed that SeNPs had no cytotoxicity on PC12 cells. Moreover, SeNPs entered cells through cellular endocytosis, which effectively attenuated Aβ25–35-induced toxicity in PC12 cells. In addition, compared with Aβ25–35 model group, SeNP pretreatment significantly enhanced the antioxidant capacity, inhibited the overproduction of reactive oxygen species (ROS), effectively regulated the inflammatory response, decreased the activity of acetylcholinesterase, significantly reduced the expression level of caspase-1 and the ratio of Bcl-2/Bax, and upregulated the expression level of p53. Furthermore, compared with Aβ25–35 model group, SeNPs effectively promoted the phosphorylation of Akt and cAMP-response element-binding protein (CREB), and upregulated the expression level of brain-derived neurotrophic factor (BDNF). In addition, the Akt inhibitor (AKT inhibitor VIII, AKTi-1/2) could reverse the protective effects of SeNPs on PC12 cells. The Akt agonist (SC79) had a similar effect on PC12 cells as that of SeNPs. Overall, this study demonstrated that biogenic SeNPs can effectively alleviate the Aβ25–35-induced toxicity in PC12 cells via Akt/CREB/BDNF signaling pathway.Keywords
Funding Information
- Innovation Foundation for Doctor Dissertation of Northwestern Polytechnical University (CX2021029)
- National Natural Science Foundation of China (32072746)
- Key Research and Development Program of Shaanxi Province (2021NY-004)
This publication has 42 references indexed in Scilit:
- Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and TherapyMolecular Neurobiology, 2014
- Management of Cognitive Determinants in Senile Dementia of Alzheimer’s Type: Therapeutic Potential of a Novel Polyherbal Drug ProductClinical Drug Investigation, 2014
- Selenium and Selenoproteins in Inflammatory Bowel Diseases and Experimental ColitisInflammatory Bowel Diseases, 2014
- BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseasesNature Reviews Neuroscience, 2013
- Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brainFree Radical Biology and Medicine, 2012
- Nutritional status of selenium in Alzheimer's disease patientsBritish Journal of Nutrition, 2009
- Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 miceFree Radical Biology and Medicine, 2009
- Pathways towards and away from Alzheimer's diseaseNature, 2004
- Anti-apoptotic proteins are oxidized by Aβ25–35 in Alzheimer's fibroblastsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2003
- Amyloid β‐peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitorsThe FASEB Journal, 2001